Klas Ola Blixt

Klas Ola Blixt


Aktuel forskning

Over past 5 years my research portfolio is broad but stays focused around four standing themes/questions;

  • can we detect aberrant glycoforms in patient material (new or improved
    biomarkers)? [1].
  • can we detect novel immune responses due to aberrant glycans (early detection, new vaccine candidates)? [2, 3].
  • can we generate diagnostic tools such as monoclonal antibodies to aberrantglycoforms and  (new therapeutics)?. [4]
  • can we modify (‘Glycocalyxificate’) membranes and cells to obtain new cellular functions [5, 6] or produce cells with new phenotypic function, differentiation, drug delivery etc.?


All four have been addressed in various research themes and generated publications (see reference list below). With our synthetic capacity we demonstrates that efficient, well- characterized serologic and molecular assays based on small synthetic peptides can be used for type specific diagnosis of Herpes Simplex 1 and 2 [7], Eppstein-Barr [8], Crimean-Congo Haemohragic Fever [9], Ebola and Varicella Zooster.

We have established an efficient phage-display microarray approach to produce novel monoclonal antibodies with the potential to target viral envelop glycoproteins [4, 10]. Our antibody program will be instrumental to generate highly specific monoclonal antibodies targeting cancer and viral epitopes.

[1] Kowa Chen, Aleksandra Gentry-Maharaj, Matthew Burnell, Catharina Steentoft, Lara Da Silva, Ulla Mandel, Ian Jacobs, Anne Dawnay, Usha Menon and Ola Blixt, Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer (2013) Journal of Proteome Research 12(3):1408-18

[2] Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. (2011) Breast Cancer Res. 13(2):R25

[3] Emiliano Cló, Stjepan Kracun, Aaron Nudelmann, Knud J. Jensen, Jan-Åke Liljeqvist, Sigvard Olofsson, Tomas Bergström and Ola Blixt Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. (2012) Journal of Virology 86(11):6268-78).

[4] Persson N, Jansson B, Stuhr-Hansen N, Kovács A, Welinder C, Danielsson L, Blixt O. A Combinatory Antibody-Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries. PLoS One. 2016 Dec 21;11(12):e0168761. doi:10.1371/journal.pone.0168761. eCollection 2016. PMID: 28002485

[5] Stuhr-Hansen N, Madl J, Villringer S, Aili U, Römer W, Blixt O. Synthesis of Cholesterol-Substituted Glycopeptides for Tailor-Made Glycocalyxification of Artificial Membrane Systems. Chembiochem. 2016 Aug 3;17(15):1403-6. doi: 10.1002/cbic.201600258. Epub 2016 Jun 17. PMID:27168414

 [6] Vagianou CD, Stuhr-Hansen N, Moll K, Bovin N, Wahlgren M, Blixt O. ABO Blood Group Antigen-Decorated Giant Unilamellar Vesicles Exhibit Distinct Interactions with Plasmodium falciparum-Infected Red Blood Cells. ACS Chem Biol. 2018 Aug 6. doi: 10.1021/acschembio.8b00635. [Epub ahead of print]

[7] Risinger C, Sørensen KK, Jensen KJ, Olofsson S, Bergström T, Blixt O. Linear Multiepitope (Glyco)peptides for Type-Specific Serology of Herpes Simplex Virus (HSV) Infections. ACS Infect Dis. 2017 May 12;3(5):360-367. doi: 10.1021/acsinfecdis.7b00001. Epub 2017 Mar 6. PMID: 28238255

[8] Isotta D’Arrigo, Emiliano Cló, Tomas Bergström, Sigvard Olofsson and Ola Blixt, Diverse IgG serum response to Epstein-Barr virus glycoprotein 350/220 revealed with O-glycopeptide microarray (2013) Glycoconjugate Journal (7):633-40.

[9] Fritzen A, Risinger C, Korukluoglu G, Christova I, Corli Hitzeroth A, Viljoen N, Burt FJ, Mirazimi A, Blixt O. Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approach. PLoS Negl Trop Dis. 2018 Jul 9;12(7):e0006598. doi: 10.1371/journal.pntd.0006598. eCollection 2018 Jul.

 [10] Wendel U, Persson N, Risinger C, Bengtsson E, Nodin B, Danielsson L, Welinder C, Nordin Fredrikson G, Jansson B, Blixt O. A novel monoclonal antibody targeting carboxymethyllysine, an advanced glycation end product in atherosclerosis and pancreatic cancer. PLoS One. 2018 Feb 8;13(2):e0191872. doi: 10.1371/journal.pone.0191872. eCollection 2018. PMID: 29420566

ID: 984797